

OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston

March 6, 2019

ALAMEDA, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- **OncoCyte Corporation (NYSE American: OCX)**, a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, CEO of OncoCyte Corporation, will be presenting at the Cowen and Company 39th Annual Health Care Conference, taking place March 11-13 at the Boston Marriott Copley Place hotel in Boston, Massachusetts.

Cowen and Company 39th Annual Health Care Conference

Date: Wednesday, March 13
Time: 10:00am Eastern Time
Location: Boston Marriott Copley Place
Webcast: <http://wsw.com/webcast/cowen52/ocx/>

About OncoCyte Corporation

OncoCyte is focused on the development and commercialization of novel, non-invasive blood ("liquid biopsy") diagnostic tests for the early detection of cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients' quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures. OncoCyte's is focusing its efforts on developing DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic and protein molecular markers to detect the presence of lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop tests for additional types of cancer based on those markers.

Investor Contacts

Bob Yedid
LifeSci Advisors, LLC
bob@lifesciadvisors.com
646-597-6989

Media Contact

Andrew Mielach
LifeSci Public Relations
amielach@lifescipublicrelations.com
646-876-5868



OncoCyte Corporation